Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer [ID6328]
Closed for comments This consultation ended on at Request commenting lead permission
4 Evaluation committee members and NICE project team
Evaluation committee members
The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee D.
Committee members are asked to declare any interests in the technology being evaluated. If it is considered there is a conflict of interest, the member is excluded from participating further in that evaluation.
The minutes of each evaluation committee meeting, which include the names of the members who attended and their declarations of interests, are posted on the NICE website.
Chair
Megan John
Chair, technology appraisal committee D
NICE project team
Each evaluation is assigned to a team consisting of 1 or more health technology analysts (who act as technical leads for the evaluation), a technical adviser, a project manager and an associate director.
George Millington
Technical lead
Albany Chandler
Technical adviser
Leena Issa
Project manager
Ian Watson
Associate director
ISBN: [to be added at publication]
How are you taking part in this consultation?
You will not be able to change how you comment later.
You must be signed in to answer questions
Question on Consultation
Question on Consultation
Question on Consultation
Question on Consultation